RT Journal Article
T1 Oral anticoagulation in chronic kidney disease with atrial fibrillation.
T2 Anticoagulación oral en la enfermedad renal crónica con fibrilación auricular.
A1 Gómez-Fernández, Pablo
A1 Martín Santana, Antonio
A1 Arjona Barrionuevo, Juan de Dios
K1 Antagonistas de la vitamina K
K1 Anticoagulant-related nephropathy
K1 Anticoagulantes orales de acción directa
K1 Atrial fibrillation
K1 Chronic kidney disease
K1 Direct-acting oral anticoagulants
K1 Enfermedad renal crónica
K1 Fibrilación auricular
K1 Nefropatía por anticoagulantes
K1 Vitamin K antagonist
AB Chronic kidney disease (CKD) and atrial fibrillation (AF) frequently coexist, amplifying the risk of cardiovascular events and mortality. In patients with CKD stage3 and non-valvular AF, direct oral anticoagulants (DOACs) have shown, compared to vitaminK antagonists (VKA), equal or greater efficacy in the prevention of stroke and systemic embolism, and greater safety. There are no randomized trials of the efficacy and safety of DOACs and VKA in advanced CKD. On the other hand, observational studies suggest that DOACs, compared to warfarin, are associated with a lower risk of acute kidney damage and generation/progression of CKD. This paper reviews the epidemiological and pathophysiological aspects of the CKD and AF association, the evidence of the efficacy and safety of warfarin and ACODs in various stages of CKD with AF as well as the comparison between warfarin and ACODs in efficacy and anticoagulant safety, and in its renal effects.
YR 2020
FD 2020-12-09
LK http://hdl.handle.net/10668/16779
UL http://hdl.handle.net/10668/16779
LA en
LA es
DS RISalud
RD Apr 17, 2025